نتایج جستجو برای: Nasal vaccine

تعداد نتایج: 152195  

Journal: :Journal of immunology 2010
Yoshiko Fukuyama Janice D King Kosuke Kataoka Ryoki Kobayashi Rebekah S Gilbert Kazunori Oishi Susan K Hollingshead David E Briles Kohtaro Fujihashi

This study was designed to investigate whether secretory-IgA (S-IgA) Abs induced by a pneumococcal surface protein A (PspA)-based nasal vaccine are necessary for prevention of streptococcal colonization. Mice nasally immunized with PspA plus a plasmid expressing Flt3 ligand (pFL) cDNA as a mucosal adjuvant showed significantly higher levels of PspA-specific S-IgA and IgG Ab responses in both pl...

Journal: :Infection and immunity 1998
B Haneberg R Dalseg E Wedege E A Høiby I L Haugen F Oftung S R Andersen L M Naess A Aase T E Michaelsen J Holst

A nasal vaccine, consisting of outer membrane vesicles (OMVs) from group B Neisseria meningitidis, was given to 12 volunteers in the form of nose drops or nasal spray four times at weekly intervals, with a fifth dose 5 months later. Each nasal dose consisted of 250 microg of protein, equivalent to 10 times the intramuscular dose that was administered twice with a 6-week interval to 11 other vol...

H. Zolfagharian N. Mohammad pour-dounighi

  The immunogenicity of ten different formulations of intranasal diphtheria and tetanus vaccines which containing different absorption enhancers, adjuvants and other excipients were determined in guinea pigs by the serum neutralization (SN) method. From these ten formulations, it was selected four formulations which gave significant immunogenicity in guinea pigs. In order to design the "final f...

In the present study, 360 male day-old broiler chicks were used to determine the effect of mixed livevaccines of Newcastle disease (ND) and infectious bronchitis (IB) on serum and local antibody responses toIB. Chicks were randomly divided into 12 treatment groups of 3 replicates and reared for 40 days on floorpens. Groups 1 to 5 received mixed ND and IB vaccine. Groups 7 to 11 received IB vacc...

Journal: :Journal of immunology 2010
Yoshikazu Yuki Tomonori Nochi Norihiro Harada Yuko Katakai Hiroaki Shibata Mio Mejima Tomoko Kohda Daisuke Tokuhara Shiho Kurokawa Yuko Takahashi Fumiko Ono Shunji Kozaki Keiji Terao Hideo Tsukada Hiroshi Kiyono

Nasal administration is an effective route for a needle-free vaccine. However, nasally administered Ags have the potential to reach the CNS directly from the nasal cavity, thus raising safety concerns. In this study, we performed real-time quantitative tracking of a nasal vaccine candidate for botulism, which is a nontoxic subunit fragment of Clostridium botulinum type A neurotoxin (BoHc/A) eff...

Journal: :Infection and immunity 2006
Adam C Schaffer Robert M Solinga Jordan Cocchiaro Marta Portoles Kevin B Kiser Allison Risley Suzanne M Randall Viviana Valtulina Pietro Speziale Evelyn Walsh Timothy Foster Jean C Lee

Staphylococcus aureus is responsible for a wide range of infections, including soft tissue infections and potentially fatal bacteremias. The primary niche for S. aureus in humans is the nares, and nasal carriage is a documented risk factor for staphylococcal infection. Previous studies with rodent models of nasal colonization have implicated capsule and teichoic acid as staphylococcal surface f...

2015
Annalisa Ciabattini Gennaro Prota Dennis Christensen Peter Andersen Gianni Pozzi Donata Medaglini

The design of heterologous prime-boost vaccine combinations that optimally shape the immune response is of critical importance for the development of next generation vaccines. Here, we tested different prime-boost combinations using the tuberculosis vaccine antigen H56 with CAF01 or CpG ODN 1826 adjuvants, administered by the parenteral and nasal routes. Using peptide-MHC class II tetramers, an...

Journal: :Vaccine 2010
D Tribble R Kaminski J Cantrell M Nelson C Porter S Baqar C Williams R Arora J Saunders M Ananthakrishnan J Sanders G Zaucha R Turbyfill E Oaks

Shigellosis is a leading cause of diarrhea worldwide prompting vaccine development. The Shigella flexneri Invaplex 50 is a macromolecular complex containing IpaB, IpaC, and LPS, formulated from an aqueous extract of virulent Shigella delivered via nasal administration. Preclinical vaccine testing demonstrated safety, immunogenicity and efficacy. An open-label dose-escalating phase 1 study evalu...

Journal: :JAMA 2021

Administering the Oxford/AstraZeneca COVID-19 vaccine through nose reduced viral shedding in animal models, a recent study led by National Institute of Allergy and Infectious Diseases (NIAID) scientist found.

2015
Hidehiko Suzuki Akihiro Watari Eri Hashimoto Miki Yonemitsu Hiroshi Kiyono Kiyohito Yagi Masuo Kondoh Jun Kunisawa Eliane Namie Miyaji

Efficient vaccine delivery to mucosal tissues including mucosa-associated lymphoid tissues is essential for the development of mucosal vaccine. We previously reported that claudin-4 was highly expressed on the epithelium of nasopharynx-associated lymphoid tissue (NALT) and thus claudin-4-targeting using C-terminal fragment of Clostridium perfringens enterotoxin (C-CPE) effectively delivered fus...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید